Abstract The aim of this study was to compare the immunoexpression of epithelial mucins (MUCs) in salivary duct cysts, papillary cystadenomas, and mucoepidermoid carcinomas and to evaluate if any of these markers could be useful for differentiating between mucoepidermoid carcinoma and papillary cystadenoma. We also sought to validate the p63 expression pattern found to differentiate between mucoepidermoid carcinoma and papillary cystadenoma. Immunoexpression of MUC1, MUC2, MUC4, MUC7, and p63 was studied and quantified in 22 mucoepidermoid carcinomas, 12 papillary cystadenomas, and 3 salivary duct cysts. The immunohistochemical evaluation was collectively performed by 3 oral pathologists. Scores and trends in proportions were assessed using the nonparametric Wilcoxon-Mann-Whitney rank sum test. Mucoepidermoid carcinomas, papillary cystadenomas, and salivary duct cysts demonstrated variable MUC expression patterns. All tumors were positive for p63 immunoexpression with p63 labeling in salivary duct cysts and papillary cystadenomas (15/15) limited to the basal layers of the cystic spaces, whereas in mucoepidermoid carcinomas (22/22) the p63 labeling extended throughout the suprabasal layers (p \ 0.001). This study adds more confirmatory data to validate that the reactivity pattern of p63 protein can be used in distinguishing between papillary cystadenoma and low-grade mucoepidermoid carcinoma. Although positive reactivity in a tumor with MUC1 and MUC4 was inconclusive, negative reactivity suggests the diagnosis of a benign PC or SDC.
Introduction
Mucoepidermoid carcinoma (MEC) is the most common malignant neoplasm of salivary glands-comprising 30 % of all malignant tumors in major and minor salivary glands [1] . MEC is a glandular epithelial tumor composed of varying proportions of mucous, epidermoid, intermediate, columnar, clear, and occasionally, oncocytic cells and is thought to arise from pluripotent reserve cells of excretory ducts [2] . Many tumors have a cystic component as well as solid cords, islands and/or sheets of tumor cells [1] . In fact, MEC is classified into low-, intermediate-, and high-grade tumors according to its amount of cystic and solid components. Low-grade tumors are often characterized by an extensive cystic component whereas high-grade tumors present more solid and cytomorphologic variability. Intermediate grade tumors are of course between these two extremes [3] [4] [5] .
Papillary cystadenoma (PC) of the salivary glands is a rare benign epithelial tumor characterized by primarily multicystic growth, intraluminal papillary proliferations, and duct-like structures [1] . Histologically, PC can resemble low-grade MECs given that it presents a similar, predominately cystic pattern, which makes the distinction between the two challenging. Epithelial mucins (MUCs) are multifunctional high molecular weight glycoproteins consisting of a linear polypeptide chain with numerous oligosaccharide-glycosylated carbohydrate chains of variable length that are different for each type of MUC, with 19 MUC-encoding genes currently identified [7] . MUCs have served as molecular markers of malignant transformation in several organs and tissues and their expression is related to the prognosis of some neoplasms, including mucoepidermoid carcinoma [7] [8] [9] [10] [11] [12] [13] [14] . Although MUC expression has been previously studied in MEC, its immunoexpression in PC has not been reported.
In 2013, the immunohistochemical expression pattern of p63 was reported to distinguish characteristic low-grade MEC from PC. Fonseca et al. [6] found that p63 expression in PC was limited to the basal layers of the tumor's cystic spaces, whereas in MEC, expression was also seen throughout the suprabasilar layers. However, after applying this to a low-grade tumor encountered in our biopsy service, the results were inconclusive due to minimal cystic epithelial layers present and those that were present showing focal areas of reactivity and nonreactivity.
The aim of the present study was to compare the immunoexpression of MUCs (MUC1, MUC2, MUC4, and MUC7) in PCs and MECs and to evaluate if any of these markers could be useful for differentiating between MEC and PC. We also sought to validate the p63 expression pattern found by Fonseca et al. [6] .
Materials and Methods
Fifteen low-grade MECs, 5 intermediate-grade MECs, 2 high-grade MECs, 12 PCs, and 3 salivary duct cysts (SDCs) derived from minor salivary glands of the oral cavity were retrieved from the surgical pathology archives of the University of Iowa College of Dentistry Surgical Oral Pathology Laboratory under the University of Iowa Institutional Review Board (201407720). These cases were used to determine immunohistochemically the expression of p63 protein, MUC1, MUC2, MUC4, and MUC7. All samples were fixed in 10 % formalin and embedded in paraffin. The original diagnoses were reviewed by 2 independent oral pathologists (EL, AP), who also screened the hematoxylin and eosin-stained slides for representative tumor samples, which included adjacent salivary gland tissue in all cases.
Immunohistochemistry (IHC) was performed in the Histology Research Laboratory of the University of Iowa Hospitals and Clinics, Department of Pathology, using the following commercially available antibodies: p63 (Dako, Carpinteria, CA), MUC1 (Abcam, Cambridge, UK), MUC2 (Abcam, Cambridge, UK), MUC4 (Abcam, Cambridge, UK), and MUC7 (Abcam, Cambridge, UK). The antibody catalog number/clone, type, dilution, and vendor information is summarized in Table 1 . Briefly, IHC was performed on 4 lm sections that were first deparaffinized, rehydrated, and subjected to heat-induced epitope retrieval in citrate buffer (pH 6.0 or pH 8.0) in a pressure cooker. After incubation with the primary antibody, the Dako EnVision Kit was used for detection. The reaction was visualized with the chromogen 3,3 0 -diaminobenzidine (DAB) (Dako Carpinteria, CA), followed by DAB Enhancer (Dako Carpinteria, CA). Slides were counterstained with Leica/Surgipath (Buffalo Grove, IL) hematoxylin.
The immunohistochemical evaluation was collectively performed by 3 oral pathologists (EL, AP, JH). For each antibody, the positivity and reactivity pattern were recorded for tumor tissue. Reactivity was considered to be positive when the reactivity intensity was equal to or stronger than the control and greater than 5 % of tumor cells reacted. In case of divergence among the oral pathologists, consensus was enforced.
Scores and trends in proportions were assessed using the nonparametric Wilcoxon-Mann-Whitney rank sum test. Data analyses were performed using SigmaStat (version 3.5; Systat Software Inc, Erkrath, Germany). The a priori level of significance was set at p \ 0.05.
Results
The clinical features are summarized in Table 2 . Examples of reactivity expression are shown in Fig. 1 . The distribution of the immunohistochemical expressions is shown in Table 3 . 
MUC2 Expression
One MEC showed reactivity for MUC2 focally in mucous cells. All other MECs (21/22) were negative for reactivity. All PCs (12/12) and SDCs (3/3) were negative for MUC2 reactivity. 
MUC7 Expression
No reactivity for MUC7 was seen in any tumor type.
Discussion
In our study we sought to compare the immunoexpression of MUCs (MUC1, MUC2, MUC4, MUC7) in salivary duct cysts (SDCs), PCs, and MECs and to evaluate if any of these markers could be useful for differentiating between MEC and PC. No variable expression pattern was found between MECs, PCs, and SDCs with MUC2 or MUC7 antibodies. Although positive reactivity in a tumor with MUC1 and MUC4 is inconclusive, negative reactivity suggests the diagnosis of a benign PC or SDC (p = 0.012 and 0.028, respectively).
Histologically, PC can demonstrate a close resemblance to those low-grade MECs with a predominately cystic pattern making the distinction between the two lesions challenging. The present study confirmed the findings of Fonseca et al. [6] that p63 protein is expressed in both tumors, but with distinctive expression patterns. In 95.5 % (21/22) of MEC cases here, the distinct expression pattern showed reactivity of cystic epithelial cells within the basilar layer and throughout the suprabasilar layers, near the lumen. However, in all cases of PCs and SDCs (15/15), the p63 reactivity was isolated to the basal cells of the cystic structures (p \ 0.001).
MUCs are proteins consisting of a linear polypeptide chain with numerous oligosaccharide-glycosylated carbohydrates chains of variable length. The role of MUCs includes acting as a molecular barrier at the epithelial surface, facilitating glandular secretory processes, and participating in signal transduction. The expression of each Table 3 Distribution n (%) of the immunohistochemical expression according to diagnosis MUC gene is specific to the organ, tissue, and cell type [7] [8] [9] . Alterations in the structure and expression of MUCs have been reported in various neoplasms. In several organs and tissues, MUCs serve as molecular markers of malignant transformation such as breast and pancreatic cancers. In various tumor types, MUC expression has also been shown to correlate with prognosis [7, [10] [11] [12] [13] [14] . This is true in several salivary gland tumor types as well. For instance, Soares et al. [15] assessed MUC1 expression in pleomorphic adenomas, recurrent pleomorphic adenomas, and carcinomas ex-pleomorphic adenoma and found that MUC1 reactivity in recurrent pleomorphic adenomas was stronger than in pleomorphic adenomas and the reactivity in carcinomas was significantly higher than in either recurrent pleomorphic adenomas or pleomorphic adenomas. Alos et al. [16] found that MUC1 and MUC4 are overexpressed in MEC cells and their expression pattern correlated with tumor differentiation. An inverse relationship was seen with high MUC1 and low MUC4 expression associated with tumor progression and worse prognosis, whereas low MUC1 expression and high MUC4 expression was associated with a better prognosis. Recent studies have shown that p40 (DNp63), a major isoform of the p63 gene, appears to be a more specific marker for squamous differentiation with great diagnostic utility in salivary gland pathology [17] [18] [19] [20] . As p63 has been previously validated in marking MECs and was used in the previous study by Fonseca et al. [21, 22] we chose this antibody, though a future similar study with use of p40 may prove interesting.
In conclusion, this study adds more confirmatory data to validate that the reactivity pattern of p63 protein can be used in distinguishing between papillary cystadenoma and low-grade mucoepidermoid carcinoma as originally reported by Fonseca et al. [6] .
